prof. MUDr. Luděk Pour, Ph.D.

2020

• Chronický stres, psychická nepohoda a deprese zvyšují četnost infekčních, autoimunitních, ale i maligních nemocí

  ADAM Zdeněk KRÁL Zdeněk KLIMEŠ J. BOLELOUCKÝ Z. POUR Luděk

  Article in Periodical

  Vnitřní lékařství, year: 2020, volume: 66, edition: 1

• Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model

  HÁJEK Roman SANDECKÁ Viera ŠPIČKA Ivan RAAB Marc GOLDSCHMIDT Hartmut BECK Susanne MINAŘÍK Jiří PAVLÍČEK Petr RADOCHA Jakub HEINDORFER Adriana JELÍNEK Tomáš STEJSKAL Lukáš BROŽOVÁ Lucie ŠEVČÍKOVÁ Sabina STRAUB Jan PIKA Tomáš POUR Luděk MAISNAR Vladimír SECKINGER Anja HOSE Dirk

  Article in Periodical

  British journal of haematology, year: 2020, volume: 190, edition: 2, DOI

• Léčba Erdheimovy-Chesterovy choroby.

  KRÁL Zdeněk KREJČÍ Marta JEŽOVÁ Marta ŠEVČÍKOVÁ Sabina ŘEHÁK Zdeněk KOUKALOVÁ Renata POUR Luděk ADAM Zdeněk

  Article in Periodical

  Transfuze a hematologie dnes, year: 2020, volume: 26, edition: 4

• Léčba histiocytózy z Langerhansových buněk u dospělých osob

  KRÁL Zdeněk ADAM Zdeněk DOUBKOVÁ Martina KREJČÍ Marta HORVÁTH Teodor DOUBEK Michael POUR Luděk ŘEHÁK Zdeněk KOUKALOVÁ R.

  Article in Periodical

  Transfuze a hematologie dnes, year: 2020, volume: 26, edition: 2

• Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma

  MATEOS MV BLADE J BRINGHEN S OCIO EM EFEBERA Y POUR Luděk GAY F SONNEVELD P GULLBO J RICHARDSON PG

  Article in Periodical

  Journal of Clinical Medicine, year: 2020, volume: 9, edition: 10, DOI

• Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data

  CAMPIONI M. AGIRREZABAL I. HAJEK R. MINARIK J. POUR Luděk SPICKA I. GONZALEZ-MCQUIRE S. JANDOVA P. MAISNAR V.

  Article in Periodical

  EUROPEAN JOURNAL OF HEALTH ECONOMICS, year: 2020, volume: 21, edition: 2, DOI

• OCEAN: a randomized Phase III study of melflufen plus dexamethasone to treat relapsed refractory multiple myeloma

  SCHJESVOLD F. ROBAK P. POUR Luděk ASCHAN J. SONNEVELD P.

  Article in Periodical

  Future Oncology, year: 2020, volume: 16, edition: 11, DOI

• Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

  GROSICKI Sebastian SIMONOVA Maryana SPICKA Ivan POUR Luděk KRIACHOK Iryrna GAVRIATOPOULOU Maria PYLYPENKO Halyna AUNER Holger W LELEU Xavier DORONIN Vadim USENKO Ganna BAHLIS Nizar J HAJEK Roman BENJAMIN Reuben DOLAI Tuphan K SINHA Dinesh K VENNER Christopher P GARG Mamta GIRONELLA Mercedes JURCZYSZYN Artur ROBAK Pawel GALLI Monica WALLINGTON-BEDDOE Craig RADINOFF Atanas SALOGUB Galina DON STEVENS BASU Supratik LIBERATI Anna M QUACH Hang GORANOVA-MARINOVA Vesselina S BILA Jelena KATODRITOU Eirini OLIYNYK Hanna KORENKOVA Sybiryna KUMAR Jeevan JAGANNATH Sundar MOREAU Phillipe LEVY Moshe WHITE Darrell GATT Moshe E FACON Thierry MATEOS Maria V CAVO Michele REECE Donna JR Larry D Anderson SAINT-MARTIN Jean-Richard JEHA Jacqueline ANITA JOSHI CHAI Yi LI Lingling PEDDAGALI Vishnuvardhan ARAZY Melina SHAH Jatin SHACHAM Sharon KAUFFMAN Michael G MELETIOS DIMOPOULOS RICHARDSON Paul G DELIMPASI Sosana

  Article in Periodical

  Lancet, year: 2020, volume: 396, edition: 10262, DOI

• Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

  MATEOS MV CAVO M BLADE J DIMOPOULOS MA SUZUKI K JAKUBOWIAK A KNOP S DOYEN C LUCIO P NAGY Z POUR Luděk COOK M GROSICKI S CREPALDI A LIBERATI AM CAMPBELL P SHELEKHOVA T YOON SS IOSAVA G FUJISAKI T GARG M KREVVATA M CHEN Y WANG JP KUDVA A UKROPEC J WROBLEWSKI S QI M KOBOS R SAN-MIGUEL J

  Article in Periodical

  Lancet, year: 2020, volume: 395, edition: 10218, DOI

• Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

  LUDWIG H PONISCH W KNOP S EGLE A HINKE A SCHREDER M LECHNER D HAJEK R GUNSILIUS E PETZER A WEISEL K NIEDERWIESER D EINSELE H WILLENBACHER W RUMPOLD H POUR Luděk JELINEK T KRENOSZ KJ MECKL A NOLTE S MELCHARDT T GREIL R ZOJER N

  Article in Periodical

  LEUKEMIA & LYMPHOMA, year: 2020, volume: 61, edition: 2, DOI